<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2015.53030</article-id><article-id pub-id-type="publisher-id">ACM-16088</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20150300000_14154011.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  阿托伐他汀联合替格瑞洛治疗急性冠脉综合症介入术后患者两种药物临床疗效的相互影响
  The Mutual Effect of Clinical Efficacy of Atorvastatin Combined with Ticagrelor for Patients with Acute Coronary Syndrome after Interventional Treatment
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>宋</surname><given-names>剑</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>刘</surname><given-names>美莲</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>朱</surname><given-names>王亮</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>陈</surname><given-names>丽珠</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>莉</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>郑</surname><given-names>玉云</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><addr-line>包头医学院研究生学院，内蒙古 包头</addr-line></aff><aff id="aff3"><addr-line>包头医学院第一附属医院，内蒙古 包头</addr-line></aff><aff id="aff2"><addr-line>null</addr-line></aff><author-notes><corresp id="cor1">* E-mail:<email>2499818657@qq.com(宋剑)</email>;</corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>07</month><year>2015</year></pub-date><volume>05</volume><issue>03</issue><fpage>188</fpage><lpage>192</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   
   目的：探究急性冠脉综合症患者介入术后使用阿托伐他汀与替格瑞洛联用两种药物临床效果及其副作用的相互影响。方法：收集我院2014年心内科入院患者120例，经临床症状和冠脉造影诊断为急性冠脉综合症，将入选患者随机分为阿托伐他汀氯吡格雷组、阿托伐他汀替格瑞洛组，测定各组患者血清尿酸、转氨酶、肌酸激酶、血小板聚集率、血脂水平等，比较在临床疗效上是否存在相互影响。结果：与氯吡格雷组相比，替格瑞洛组在抗血小板聚集率有统计学意义(P &lt; 0.05)，两组血脂血平无统计学意义(P &lt; 0.05)。结论：尽管研究显示阿托伐他汀、替格瑞洛存在CYP3A4的竞争性抑制，药动学方面有一定影响，但短期各自的临床疗效改变不显著。 Objective: To explore the clinical effects and side effect of atorvastatin combined with ticagrelor for patients with acute coronary syndrome after interventional treatment. Methods: 120 cases of hospitalized patients in our Department of Cardiology of 2014 was collected, according to the clinical symptoms and coronary angiography in the diagnosis of acute coronary syndrome (ACS), the selected patients were randomly divided into the atorvastatin clopidogrel group and atorvastatin for Greg groups, we measured serum uric acid, transaminase, creatine kinase, platelet aggregation rate, lipid levels, etc. of the patients and compared whether there was influence of the clinical curative effect on each other. Results: There were significant differences between clopidogrel group and Greg los group in blood platelet aggregation rate (P &lt; 0.05), and no significant differences in blood lipid levels (P &gt; 0.05). Conclusions: Studies have shown competitive inhibition of CYP3A4 between atorvastatin and ticagrelor, resulting in certain influence on the pharmacokinetics, however, their clinical efficacy showed no significant change in the short term when used in combination.
    
  
 
</p></abstract><kwd-group><kwd>替格瑞洛，阿托伐他汀，急性冠脉综合症，药物相互作用, Ticagrelor</kwd><kwd> Atorvastatin</kwd><kwd> Acute Coronary Syndrome</kwd><kwd> Drug Interaction</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>阿托伐他汀联合替格瑞洛治疗急性冠脉综合症介入术后患者两种药物临床疗效的相互影响<sup> </sup></title><p>宋剑<sup>1*</sup>，刘美莲<sup>2</sup>，朱王亮<sup>2</sup>，陈丽珠<sup>2</sup>，李莉<sup>2</sup>，郑玉云<sup>2</sup></p><p><sup>1</sup>包头医学院研究生学院，内蒙古 包头</p><p><sup>2</sup>包头医学院第一附属医院，内蒙古 包头</p><p>Email: <sup>*</sup>2499818657@qq.com</p><p>收稿日期：2015年8月27日；录用日期：2015年9月17日；发布日期：2015年9月24日</p><disp-formula id="hanspub.16088-formula256"><graphic xlink:href="http://html.hanspub.org/file/7-1570166x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：探究急性冠脉综合症患者介入术后使用阿托伐他汀与替格瑞洛联用两种药物临床效果及其副作用的相互影响。方法：收集我院2014年心内科入院患者120例，经临床症状和冠脉造影诊断为急性冠脉综合症，将入选患者随机分为阿托伐他汀氯吡格雷组、阿托伐他汀替格瑞洛组，测定各组患者血清尿酸、转氨酶、肌酸激酶、血小板聚集率、血脂水平等，比较在临床疗效上是否存在相互影响。结果：与氯吡格雷组相比，替格瑞洛组在抗血小板聚集率有统计学意义(P &lt; 0.05)，两组血脂血平无统计学意义(P &lt; 0.05)。结论：尽管研究显示阿托伐他汀、替格瑞洛存在CYP3A4的竞争性抑制，药动学方面有一定影响，但短期各自的临床疗效改变不显著。</p><p>关键词 :替格瑞洛，阿托伐他汀，急性冠脉综合症，药物相互作用</p><disp-formula id="hanspub.16088-formula257"><graphic xlink:href="http://html.hanspub.org/file/7-1570166x7_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s3"><title>1. 引言</title><p>替格瑞洛是一种新型的P2Y12受体拮抗剂，目前主要用于治疗急性冠脉综合症(ACS)患者的抗血小板治疗，国际多中心临床研究PLATO显示，替格瑞洛相比较氯吡格雷，弥补了起效慢、个体疗效差异大等不足[<xref ref-type="bibr" rid="hanspub.16088-ref1">1</xref>] -[<xref ref-type="bibr" rid="hanspub.16088-ref4">4</xref>] 。他汀类药物也称3-羟基3-甲基戊二酰辅酶A还原酶抑制剂，能够显著降低TC、LDL-C、ApoB，也能降低TG和轻度升高HDL-C，此外他汀类还具有抗炎和保护血管内皮的功能，能明显降低ACS病死率及冠状动脉事件发生率，是目前指南推荐的治疗ACS的临床一线用药[<xref ref-type="bibr" rid="hanspub.16088-ref5">5</xref>] 。在两种药物无严重药物相互作用的情况下，替格瑞洛经常会与他汀类药物联合应用。替格瑞洛与阿托伐他汀都经CYP3A4途径代谢，两种药物联用可能在肝脏代谢时产生竞争性抑制，其结果可能影响替格瑞洛的抗血小板作用，也可能减少阿托伐他汀的代谢而增加其疗效和不良反应。本研究旨在观察阿托伐他汀与替格瑞洛联用后对其相互临床疗效及不良反应的影响。</p></sec><sec id="s4"><title>2. 资料和方法</title><sec id="s4_1"><title>2.1. 一般资料</title><p>收集包头医学院第一附属医院2014年心内科入院患者经临床症状、体征、实验室检查、冠状动脉造影诊断为ACS患者，随机分成替格瑞洛与氯吡格雷两组，分别为60例，排除血液系统疾病、肝肾功能异常，有活动性出血或高危出血患者、有颅内出血病史者，入院前使用过其他抗血小板药的患者等。所有患者在给药前记录年龄体质量、性别、基础疾病、吸烟与否，并全程记录患者联合用药情况。若患者出现任何药物过敏、呼吸困难、转氨酶升高至超过正值上限3倍以上等不良反应即停药退出本研究。</p></sec><sec id="s4_2"><title>2.2. 方法</title><p>两组患者在确诊后给予阿司匹林100 mg/d，阿托伐他汀钙40 mg/d，美托洛尔25 mg/d，替格瑞洛组初始给予180 mg负荷计量，此后90 mg bid 维持，氯吡格雷组给予300 mg负荷后给予75 mg/d维持，两组患者都行冠状动脉支架置入术，术后均给予普通肝素钠5000 u，每12小时1次，共计4天，记录患者入前、用药2周高敏C反应蛋白、血脂、血小板聚集率、肝功、肾功以及肌酶水平，随访患者从入院开始到3个月内患者不良反应的发生情况[<xref ref-type="bibr" rid="hanspub.16088-ref6">6</xref>] ，不良事件发生参照患者终点实验[<xref ref-type="bibr" rid="hanspub.16088-ref7">7</xref>] 。</p></sec><sec id="s4_3"><title>2.3. 统计方法</title><p>所有数据均采用SPSS 17.0软件进行统计处理，定量资料以均数&#177;标准差表示(<inline-formula><inline-graphic xlink:href="http://html.hanspub.org/file/7-1570166x8_hanspub.png" xlink:type="simple"/></inline-formula>)、组间比较采用t检验，定性资料采用c<sup>2</sup>检验或fisher确切概率法，P &lt; 0.05为差异有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><p>1) 两组患者不良事件发生率比较</p><p>随访患者3个月，轻微出血氯吡格雷组较替格瑞洛组发生率较高，呼吸困难替格瑞洛组较氯吡格雷组发生率高，但都无统计学意义：血栓事件、再发心绞痛、卒中、心血管死亡、主要出血等事件两种发生率无差异，无统计学意义，见表1。</p><p>2) 治疗前后两组患者低密度脂蛋白(LDL)、尿素、肌酐、天门冬氨酸氨基转移酶(AST)、谷氨酰胺氨基转移酶、肌酸激酶(CK)无统计学差异(P &gt; 0.05)，但治疗前后两组血小板聚集率/高敏C反应蛋白(CRP)水平有统计学差异(P &lt; 0.05)，见表2(a)~(d)。</p></sec><sec id="s6"><title>4. 讨论</title><p>替格瑞洛作为新型P2Y12受体拮抗剂在多国临床指南推荐中提高到I类推荐。其特殊性在于无需经肝脏代谢激活即可直接发挥抗血小板作用，作用速度较氯吡格雷快，其次替格瑞洛与P2Y12受体为可逆性结合，对ADP诱导的血小板聚集具有非竞争性抑制作用，而氯吡格雷与血小板受体结合为不可逆，出血风险较替格瑞洛大。针对氯吡格雷作用起效较缓慢、作用中效、人群变异多、作用不可逆、出血风险高等局限性[<xref ref-type="bibr" rid="hanspub.16088-ref2">2</xref>] -[<xref ref-type="bibr" rid="hanspub.16088-ref4">4</xref>] ，替格瑞洛可以弥补以上不足。Steiner等研究证明替格瑞洛可以显著抑制血小板的聚集证明替格瑞洛比较氯吡格雷具有更加迅速和更加强的抗血小板聚集作用[<xref ref-type="bibr" rid="hanspub.16088-ref8">8</xref>] ，因此本实验结果两组患者血小板聚集率替格瑞洛组较氯吡格雷组低(P = 0.03)，有统计学差异。</p><p>替格瑞洛主要经CYP3A4代谢与阿托伐他汀有共同的代谢通道，理论上讲两种药物联用存在底物水平的竞争，通过其药动学的相互作用影响药效学。Tend等[<xref ref-type="bibr" rid="hanspub.16088-ref9">9</xref>] 研究显示，因为通过CYP3A4代谢，替格瑞洛可使阿托伐他汀酸的AUC和Cmax分别升高36%和23%，且所有阿托伐他汀酸代谢产物的AUC和C<sub>max</sub>亦出现相似升高，有些患者甚至会增加至2~3倍，而阿托伐他汀对替格瑞洛的血浆浓度无影响。C<sub>max</sub>和F直接关系到药物的疗效和安全性，这些药动学上的变化可能会因此进一步影响其临床疗效及不良反应。</p><p>在不良反应方面，替格瑞洛可能引起尿酸增高、出血事件和呼吸困难[<xref ref-type="bibr" rid="hanspub.16088-ref6">6</xref>] [<xref ref-type="bibr" rid="hanspub.16088-ref10">10</xref>] ；阿托伐他汀常见不良反应为转氨酶和血清肌酸激酶升高。本研究结果显示2组间在出血事件、呼吸困难方面的差异均无统计学意义(P &gt; 0.05)，表明阿托伐他汀不影响替格瑞洛的临床疗效，不增加不良反应，这应与阿托伐他汀对</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of the incidence of adverse events between two group</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >不良事件</th><th align="center" valign="middle" >氯吡格雷组</th><th align="center" valign="middle" >替格瑞洛组</th><th align="center" valign="middle" >P值</th></tr></thead><tr><td align="center" valign="middle" >主要出血 次要出血 轻微出血 血栓事件 再发心绞痛 心血管死亡 呼吸困难 卒中</td><td align="center" valign="middle" >0 2 6 0 2 1 0 0</td><td align="center" valign="middle" >0 2 1 0 1 1 1 0</td><td align="center" valign="middle" >* 1.0 0.114 * 1.0 1.0 1.0 *</td></tr></tbody></table></table-wrap><p>表1. 两组不良事件发生率比较</p><p>注：*表示未出阳性结果，无须统计</p><table-wrap-group id="2"><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Comparison of the observed values of patients between two group</title></caption><table-wrap id="2_1"><caption><title> (b)</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  colspan="2"  >LDL/%</th><th align="center" valign="middle"  colspan="2"  >血小板聚集率/%</th></tr></thead><tr><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td></tr><tr><td align="center" valign="middle" >A组(N = 60) B组(N = 60) P值</td><td align="center" valign="middle" >2.9 &#177; 0.4 2.7 &#177; 0.6 0.64</td><td align="center" valign="middle" >2.4 &#177; 0.5 2.2 &#177; 0.3 0.21</td><td align="center" valign="middle" >57.5 &#177; 4.7 58.4 &#177; 5.2 0.75</td><td align="center" valign="middle" >51.2 &#177; 4.1 42.4 &#177; 3.1 0.03</td></tr></tbody></table></table-wrap><table-wrap id="2_2"><caption><title> (c)</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  colspan="2"  >AST/(U/L)</th><th align="center" valign="middle"  colspan="2"  >ALT (U/L)</th></tr></thead><tr><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td></tr><tr><td align="center" valign="middle" >A组(N = 60) B组(N = 60) P值</td><td align="center" valign="middle" >36.4 &#177; 4.2 35.7 &#177; 4.5 0.47</td><td align="center" valign="middle" >42.4 &#177; 6.2 39.5 &#177; 5.3 0.15</td><td align="center" valign="middle" >37.6 &#177; 4.2 38.4 &#177; 3.2 0.45</td><td align="center" valign="middle" >47.2 &#177; 5.1 48.4 &#177; 3.1 0.19</td></tr></tbody></table></table-wrap><table-wrap id="2_3"><caption><title> (d)</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  colspan="2"  >尿酸/(μmol/L)</th><th align="center" valign="middle"  colspan="2"  >肌酐(μmol/L)</th></tr></thead><tr><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td></tr><tr><td align="center" valign="middle" >A组(N = 60) B组(N = 60) P值</td><td align="center" valign="middle" >326.4 &#177; 84.6 325.7 &#177; 82..5 0.53</td><td align="center" valign="middle" >343.3 &#177; 86.2 350.5 &#177; 85.3 0.12</td><td align="center" valign="middle" >68.6 &#177; 3.2 65.4 &#177; 4.1 0.37</td><td align="center" valign="middle" >73.2 &#177; 4.1 81.7 &#177; 3.9 0.17</td></tr></tbody></table></table-wrap><table-wrap id="2_4"><caption><title></title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >组别</th><th align="center" valign="middle"  colspan="2"  >CK/(μmol/L)</th><th align="center" valign="middle"  colspan="2"  >CRP (μmol/L)</th></tr></thead><tr><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td><td align="center" valign="middle" >治疗前</td><td align="center" valign="middle" >治疗后</td></tr><tr><td align="center" valign="middle" >A组(N = 60) B组(N = 60) P值</td><td align="center" valign="middle" >127.4 &#177; 24.6 125.7 &#177; 22..5 0.44</td><td align="center" valign="middle" >142.3 &#177; 26.2 137.5 &#177; 25.3 0.15</td><td align="center" valign="middle" >11.6 &#177; 4.2 10.4 &#177; 3.9 0.67</td><td align="center" valign="middle" >9.2 &#177; 1.1 5.7 &#177; 1.9 0.03</td></tr></tbody></table></table-wrap></table-wrap-group><p>表2. 两组患者观察值比较</p><p>注：A：阿托伐他汀氯吡格雷组，B：阿托伐他汀替格瑞洛组</p><p>替格瑞洛的药动学无影响有关；而替格瑞洛尽管对阿托伐他汀存在药动学上有影响，但对40 mg的阿托伐他汀而言，这种相互作用并无临床意义，不影响其治疗作用和不良反应发生率。</p><p>本研究局限之处在于观察的样本量较小，随访时间短，且没有比较不同剂量他汀类药物与替格瑞洛联用后临床疗效的差异，更大剂量阿托伐他汀和替格瑞洛是否存在明显的药物相互作用还尚不清楚。但就本次研究结果来看，40 mg阿托伐他汀联合90 mg替格瑞洛bid在治疗急性冠脉综合征患者当中，两种药治疗物效果不会相互影响，药物副作用也不会增加。</p></sec><sec id="s7"><title>文章引用</title><p>宋 剑,刘美莲,朱王亮,陈丽珠,李 莉,郑玉云. 阿托伐他汀联合替格瑞洛治疗急性冠脉综合症介入术后患者两种药物临床疗效的相互影响 The Mutual Effect of Clinical Efficacy of Atorvastatin Combined with Ticagrelor for Patients with Acute Coronary Syndrome after Interventional Treatment[J]. 临床医学进展, 2015, 05(03): 188-192. http://dx.doi.org/10.12677/ACM.2015.53030</p></sec><sec id="s8"><title>参考文献 (References)</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.16088-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Shand, J.A., Menown, I.B. and Storey, R.F. (2011) Ticagrelor: From concept to clinical evaluation. Biomarkers in Medicine, 5, 53-62. &lt;br&gt;http://dx.doi.org/10.2217/bmm.11.4</mixed-citation></ref><ref id="hanspub.16088-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Abtahian, F., Yonetsu, T., Vergallo, R., Jia, H.B., Kato, K., Tian, J.W., et al. (2013) Ticagrelor immediately prior to stentmg is associated with smaller residual thrombus in patients with acute coronary syndrome. International Journal of Cardiology, 168, 3099-3101. &lt;br&gt;http://dx.doi.org/10.1016/j.ijcard.2013.04.076</mixed-citation></ref><ref id="hanspub.16088-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Steg, P.G., Harrington, R.A., Emanuelsson, H., Katus, H.A., Mahaffey, K.W., Meier, B., et al. (2013) Stent thrombosis with ticagrelor versus clopidogrel in patients with acute co-ronary syndromes: An analysis from the prospective, randomized PLATO trial. Circulation, 128, 1055-1065.</mixed-citation></ref><ref id="hanspub.16088-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Kohli, P., Wallentin, L., Reyes, E., Horrow, J., Husted, S., Angiolillo, D.J., et al. (2013) Reduction in first and recurrent cardiovascular events with ticagrelor compared with clopidogrel in the PLATO study. Circulation, 127, 673-680.</mixed-citation></ref><ref id="hanspub.16088-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Ferri, N., Corsini, A. and Bellosta, S. (2013) Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties. Drugs, 73, 1681-1709. &lt;br&gt;http://dx.doi.org/10.1007/s40265-013-0126-z</mixed-citation></ref><ref id="hanspub.16088-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">龚世菊, 张志刚, 谭文明 (2015) 辛伐他汀与替格瑞洛联用后对相互临床疗效的影响. 中国医院用药评价与分析, 6, 737-739.</mixed-citation></ref><ref id="hanspub.16088-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Wallentin, L., Becker, R.C., Budaj, A., Cannon, C.P., Emanuelsson, H., Held, C., et al. (2009) Ticagredor versus clopidogrel in patients with acute coronary syndromes. The New England Journal of Medicine, 361, 1045-1057</mixed-citation></ref><ref id="hanspub.16088-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Steiner, S., Moertl, D., Chen, L., Coyle, D. and Wells, G.A. (2012) Network meta-analysis ticagrelor, high- and standard-dose clopidogrel in patients of prasugrel, scheduled for percutaneoucoronary interventions. Thrombosis and Haemostasis, 108, 318-327. &lt;br&gt;http://dx.doi.org/10.1160/TH11-08-0586</mixed-citation></ref><ref id="hanspub.16088-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Tend, R., Mitchell, P.D. and Butler, K.A. (2013) Phaimacokinetic interaction studies of co-administration of ticagrclor and atorvastatin or simvastatin in healthy volunteers. European Journal of Clinical Pharmacology, 69, 177-187.</mixed-citation></ref><ref id="hanspub.16088-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Catttaneo, M. and Faioni, E.M. (2012) Why does ticagrelor induce dyspnea. Thrombosis and Haemostasis, 108, 1031- 1036. &lt;br&gt;http://dx.doi.org/10.1160/TH12-08-0547</mixed-citation></ref></ref-list></back></article>